Pharmaceutical companies with covid-19 drugs in their portfolios reported some of the best earnings in the June quarter, even as the overall medicine market was down as the lockdown disrupted services at hospital out-patient departments and elective surgeries.“All those who had some covid drugs did well, and those who had HCQ in their portfolio did extraordinarily well.
Ipca was the biggest gainer. They posted almost four-fold profit from HCQ. Alembic is India’s largest manufacturer of azithromycin.